Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)

What is it about?

Reducing the levels of the hormone cortisol in the brain has emerged as a potential method of treating memory impairments in Alzheimer's disease. We describe the discovery of a potential medicine to treat these memory impairments. The results of initial tests in healthy humans are described.

Featured Image